Trial Profile
A Phase I/II, Open label, Dose Finding Study to Assess the Safety, Tolerability and Efficacy of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Tebentafusp (Primary)
- Indications Malignant melanoma; Uveal melanoma
- Focus Adverse reactions; First in man
- Sponsors Immunocore
- 19 Apr 2023 Results of pooled analysis assessing the safety and efficacy from tebentafusp treated mUM patients with orbital lesions including intraocular lesions from IMCgp100-01 (n=19), IMCgp100-102 (n=146) and IMCgp100-202 (n=245) trials, presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 13 Sep 2021 According to an Immunocore media release, data form the study will be presented at the European Society for Medical Oncology (ESMO) Congress 2021.
- 18 Aug 2020 Results published in the Clinical Cancer Research.